Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

380R-1

Sigma-Aldrich

Arginase-1 (SP156) Rabbit Monoclonal Antibody

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Código UNSPSC:
12352204
NACRES:
NA.41
En este momento no podemos mostrarle ni los precios ni la disponibilidad

origen biológico

rabbit

Nivel de calidad

100
500

conjugado

unconjugated

forma del anticuerpo

culture supernatant

tipo de anticuerpo

primary antibodies

clon

SP156, monoclonal

descripción

For In Vitro Diagnostic Use in Select Regions (See Chart)

Formulario

buffered aqueous solution

reactividad de especies

human

envase

vial of 0.1 mL concentrate (380R-14)
vial of 0.5 mL concentrate (380R-15)
bottle of 1.0 mL predilute (380R-17)
vial of 1.0 mL concentrate (380R-16)
bottle of 7.0 mL predilute (380R-18)

fabricante / nombre comercial

Cell Marque®

técnicas

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

isotipo

IgG

control

hepatocellular carcinoma, normal liver

Condiciones de envío

wet ice

temp. de almacenamiento

2-8°C

visualización

cytoplasmic, nuclear

Información sobre el gen

human ... ARG1(383)

Descripción general

Arginase is a key metalloenzyme of the urea cycle responsible for the hydrolysis of L-arginine to L-ornithine and urea.[1] Two main isoforms exist, arginase-1 and arginase-2, encoded by different genes and with different tissue distributions. The arginase-1 isoform is a cytosolic protein that is produced by normal liver tissue and is typically expressed in hepatocellular carcinoma.[1] Arginase-1 (SP156) is used as an immunohistochemical marker to aid in the identification of hepatocellular carcinoma.

Calidad


IVD

IVD

IVD

RUO

Ligadura / enlace

Arginase-1 Positive Control Slides, Product No. 380S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Forma física

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Nota de preparación

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Otras notas

For Technical Service please contact: 800-665-7284 or email: [email protected]

Información legal

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Benign and malignant tumors of the liver
Linda DF
Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas, 2nd ed., 1291-1325 (2009)
R L Zimmerman et al.
Cancer, 93(4), 288-291 (2001-08-17)
Diagnosing liver tumors by fine-needle aspiration biopsy is safe and accurate. However, there are cases that prove diagnostically difficult. Traditionally, immunostains for alpha-fetoprotein and polyclonal carcinoembryonic antigen have been used to distinguish adenocarcinomas from hepatocellular carcinomas (HCCs). In poorly differentiated
Alexandre Sherlley Casimiro Onofre et al.
Cancer, 111(4), 259-268 (2007-06-15)
Difficulties with cytologic diagnoses on fine-needle aspiration cytology (FNAC) of the liver can be overcome by the application of immunocytochemical panels applied on smears. The aim of the current study was to analyze the performance of a panel of monoclonal
T H Niemann et al.
Cancer, 87(5), 295-298 (1999-10-28)
Fine-needle aspiration biopsy (FNAB) is frequently used to diagnose mass lesions in the liver. Differentiating metastatic adenocarcinoma from primary hepatocellular carcinoma can be difficult. Despite a number of morphologic criteria, there remain occasional cases in which the cytologic features fail
H B el-Serag
Clinics in liver disease, 5(1), 87-107 (2001-02-24)
The epidemiology of hepatocellular carcinoma (HCC) is characterized by marked differences between genders, ethnic groups, and geographic regions. These variations are explained by the nature, frequency, and time of acquisition of the major risk factors for cirrhosis--namely hepatitis B virus

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico